Cargando…

Novel and Potent Small Molecules against Melanoma Harboring BRAF Class I/II/III Mutants for Overcoming Drug Resistance

Melanoma accounts for the majority of skin cancer deaths. About 50% of all melanomas are associated with BRAF mutations. BRAF mutations are classified into three classes with regard to dependency on RAF dimerization and RAS signaling. The most frequently occurring class I BRAF V600 mutations are sen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Namkyoung, Shin, Injae, Lee, Jiwon, Jeon, Eunhye, Kim, Younghoon, Ryu, Seongshick, Ju, Eunhye, Cho, Wonjeong, Sim, Taebo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038755/ https://www.ncbi.nlm.nih.gov/pubmed/33917428 http://dx.doi.org/10.3390/ijms22073783

Ejemplares similares

Anti-cancer effects of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives on hepatocellular carcinoma harboring FGFR4 activation
por: Nam, Yunju, et al.
Publicado: (2021)

Novel Small Molecules Capable of Blocking mtRAS-Signaling Pathway
por: Kim, Namkyoung, et al.
Publicado: (2021)

Identification of Thiazolo[5,4-b]pyridine Derivatives as c-KIT Inhibitors for Overcoming Imatinib Resistance
por: Nam, Yunju, et al.
Publicado: (2022)

Anti-Tumor Activity of AZD4547 Against NTRK1 Fusion Positive Cancer Cells Through Inhibition of NTRKs
por: Cho, Hanna, et al.
Publicado: (2021)

Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations
por: Obaid, Nourah Mohammad, et al.
Publicado: (2017)

Procaspase activating compound 1 controls tetracycline repressor-regulated gene expression system
por: Song, Chiman, et al.
Publicado: (2019)

Natural and Synthetic Lactones Possessing Antitumor Activities
por: Kim, Younghoon, et al.
Publicado: (2021)

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Dabrafenib for treatment of BRAF-mutant melanoma
por: Kainthla, Radhika, et al.
Publicado: (2013)

BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells
por: Goulielmaki, Maria, et al.
Publicado: (2016)

Raman-Based in Situ Monitoring of Changes in Molecular Signatures during Mitochondrially Mediated Apoptosis
por: Shin, Hyeon Jeong, et al.
Publicado: (2019)

Illness Perceptions, Self-Care Management, and Clinical Outcomes According to Age-Group in Korean Hemodialysis Patients
por: Kim, Sisook, et al.
Publicado: (2019)

Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF
por: Kim, Jae-Hyeon, et al.
Publicado: (2017)

Optimizing the treatment of BRAF mutant melanoma
por: Settleman, Jeff
Publicado: (2014)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

AK2 is an AMP-sensing negative regulator of BRAF in tumorigenesis
por: Kim, Hyunjoo, et al.
Publicado: (2022)

Lethal Consequences of Overcoming Metabolic Restrictions Imposed on a Cooperative Bacterial Population
por: Goo, Eunhye, et al.
Publicado: (2017)

Recognition of BRAF by CDC37 and Re-Evaluation of the Activation Mechanism for the Class 2 BRAF-L597R Mutant
por: Bjorklund, Dennis M., et al.
Publicado: (2022)

Giant lung metastasis of NRAS-mutant melanoma in a 24-year-old patient with a history of BRAF-mutant conventional melanoma harboring Spitzoid morphology: a case report
por: Vachtenheim, Jiri, et al.
Publicado: (2020)

Variations of BRAF mutant allele percentage in melanomas
por: Hélias-Rodzewicz, Zofia, et al.
Publicado: (2015)

Novel combination therapies for BRAF-mutant melanoma
por: McArthur, Grant A
Publicado: (2015)

Current Advances in the Treatment of BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2020)

Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib
por: Goodall, Megan L, et al.
Publicado: (2014)

Identification of 1H-pyrazolo[3,4-b]pyridine derivatives as potent ALK-L1196M inhibitors
por: Nam, Yunju, et al.
Publicado: (2019)

Exploring Community Leaders’ Understanding and Attitudes Toward Depression Among Older Korean Americans
por: Kim, Eunhye
Publicado: (2020)

Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF(V600E)-mutant melanoma
por: Harris, Antoneicka L., et al.
Publicado: (2017)

The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients
por: Lin, Quan, et al.
Publicado: (2019)

Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
por: Jain, Tania, et al.
Publicado: (2015)

Three cases of BRAF-mutant melanoma with divergent differentiation masquerading as sarcoma
por: Cilento, Michael A., et al.
Publicado: (2022)

Evaluation of growth changes induced by functional appliances in children with Class II malocclusion: Superimposition of lateral cephalograms on stable structures
por: Oh, Eunhye, et al.
Publicado: (2020)

Machine Learning Applications for the Development of a Questionnaire to Identify Sasang Constitution Typology
por: Kim, Soon Mi, et al.
Publicado: (2022)

Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring BRAF V600E Mutation
por: Kwon, Jeong-Hwa, et al.
Publicado: (2018)

Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma
por: Chan, Xian Yang, et al.
Publicado: (2017)

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation
por: Caliò, Anna, et al.
Publicado: (2016)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

BRAF-mutant hematopoietic malignancies
por: Abdel-Wahab, Omar, et al.
Publicado: (2014)

Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment
por: Mak, Gabriel, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_a37r0aaks3qj8oj221fqamh4p2